333 related articles for article (PubMed ID: 29442526)
1. Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis.
Nisticò S; Del Duca E; Torchia V; Gliozzi M; Bottoni U; Muscoli C
Int J Immunopathol Pharmacol; 2018; 32():2058738418757925. PubMed ID: 29442526
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.
Elías I; Ortega-Joaquín N; de la Cueva P; Del Pozo LJ; Moreno-Ramírez D; Boada A; Aguilar M; Mirada A; Mosquera E; Gibbons C; Oyagüez I
Actas Dermosifiliogr; 2016; 107(6):498-508. PubMed ID: 27130804
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.
Athanasakis K; Boubouchairopoulou N; Tarantilis F; Tsiantou V; Kontodimas S; Kyriopoulos J
Clin Ther; 2017 May; 39(5):993-1002. PubMed ID: 28449867
[TBL] [Abstract][Full Text] [Related]
4. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system.
Colombo GL; Chimenti S; Di Matteo S; Fargnoli MC; Frascione P; Silipo V; Peris K
G Ital Dermatol Venereol; 2010 Oct; 145(5):573-81. PubMed ID: 20930692
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomy of drugs used in the treatment of actinic keratoses.
Nisticò S; Torchia V; Gliozzi M; Bottoni U; Del Duca E; Muscoli C
Int J Immunopathol Pharmacol; 2016 Dec; 29(4):796-804. PubMed ID: 27207444
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
[TBL] [Abstract][Full Text] [Related]
9. A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.
Jansen MHE; Kessels JPHM; Merks I; Nelemans PJ; Kelleners-Smeets NWJ; Mosterd K; Essers BAB
Br J Dermatol; 2020 Oct; 183(4):738-744. PubMed ID: 31961446
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic evaluations in the treatment of actinic keratoses.
Tolley K; Argenziano G; Calzavara-Pinton PG; Larsson T; Ryttig L
Int J Immunopathol Pharmacol; 2017 Jun; 30(2):178-181. PubMed ID: 28580871
[TBL] [Abstract][Full Text] [Related]
11. Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Jedlowski PM
J Cutan Med Surg; 2023; 27(1):39-43. PubMed ID: 36495205
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients.
Norrlid H; Norlin JM; Holmstrup H; Malmberg I; Sartorius K; Thormann H; Jemec GBE; Ragnarson Tennvall G
J Dermatolog Treat; 2018 Feb; 29(1):68-73. PubMed ID: 28658998
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States.
Asche CV; Zografos P; Norlin JM; Urbanek B; Mamay C; Makin C; Erntoft S; Chen CC; Hines DM; Mark Siegel D
Value Health; 2016; 19(2):239-48. PubMed ID: 27021759
[TBL] [Abstract][Full Text] [Related]
15. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp.
Stockfleth E; Harwood CA; Serra-Guillén C; Larsson T; Østerdal ML; Skov T
Br J Dermatol; 2018 Feb; 178(2):433-442. PubMed ID: 29030864
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility of first-line actinic keratosis treatments in Finland.
Soini EJ; Hallinen T; Sokka AL; Saarinen K
Adv Ther; 2015 May; 32(5):455-76. PubMed ID: 26006101
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model.
Wilson EC
Pharmacoeconomics; 2010; 28(11):1055-64. PubMed ID: 20936887
[TBL] [Abstract][Full Text] [Related]
18. Clinical Response to Ingenol Mebutate in Patients With Actinic Keratoses.
Batalla A; Flórez Á; Feal C; Peón G; Abalde MT; Salgado-Boquete L; de la Torre C
Actas Dermosifiliogr; 2015 Dec; 106(10):e55-61. PubMed ID: 26055975
[TBL] [Abstract][Full Text] [Related]
19. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
[TBL] [Abstract][Full Text] [Related]
20. Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: a pilot study.
Jubert-Esteve E; Del Pozo-Hernando LJ; Izquierdo-Herce N; Bauzá-Alonso A; Martín-Santiago A; Jones-Caballero M
Actas Dermosifiliogr; 2015 Oct; 106(8):644-50. PubMed ID: 26130156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
